1Polanczyk, GV, Salum, GA, Sugaya, LS, Caye, A, Rohde, LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015; 56: 345–65.
2Kessler, RC, Adler, L, Barkley, R, Biederman, J, Conners, CK, Demler, O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716–23.
3Huang, CL, Chu, CC, Cheng, TJ, Weng, SF. Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. PLoS One 2014; 9(4): e95014.
4Yoshimasu, K, Barbaresi, WJ, Colligan, RC, Voigt, RG, Killian, JM, Weaver, AL, et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population-based birth cohort study. J Child Psychol Psychiatry 2012; 53: 1036–43.
5Balazs, J, Kereszteny, A. Attention-deficit/hyperactivity disorder and suicide: a systematic review. World J Psychiatry 2017; 7: 44–59.
6Altun, C, Guven, G, Akgun, OM, Acikel, C. Dental injuries and attention-deficit/hyperactivity disorder in children. Spec Care Dentist 2012; 32: 184–9.
7Ertan, C, Ozcan, OO, Pepele, MS. Paediatric trauma patients and attention deficit hyperactivity disorder: correlation and significance. Emerg Med J 2012; 29: 911–4.
8Tai, YM, Gau, SS, Gau, CS. Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan. Res Dev Disabil 2013; 34: 1100–8.
9Vaa, T. ADHD and relative risk of accidents in road traffic: a meta-analysis. Accid Anal Prev 2014; 62: 415–25.
10Curry, AE, Metzger, KB, Pfeiffer, MR, Elliott, MR, Winston, FK, Power, TJ. Motor vehicle crash risk among adolescents and young adults with attention-deficit/hyperactivity disorder. JAMA Pediatrics 2017; 171: 756–63.
11Barbaresi, WJ, Colligan, RC, Weaver, AL, Voigt, RG, Killian, JM, Mortality, KS. ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics 2013; 131: 637–44.
12Dalsgaard, S, Ostergaard, SD, Leckman, JF, Mortensen, PB, Pedersen, MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385: 2190–6.
13London, AS, Landes, SD. Attention deficit hyperactivity disorder and adult mortality. Prev Med 2016; 90: 8–10.
14Chen, VC, Chan, HL, Wu, SI, Lee, M, Lu, ML, Liang, HY, et al. Attention-deficit/hyperactivity disorder and mortality risk in Taiwan. JAMA Network Open 2019; 2(8): e198714.
15Cairney, J. Deficits in attention, motor control, and perception and increased risk of injury in children. Dev Med Child Neurol 2014; 56: 1040–1.
16Jerome, L, Habinski, L, Segal, A. Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique. Curr Psychiatry Rep 2006; 8: 416–26.
17Vaughan, B, Kratochvil, CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2012; 21: 941–55.
18MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86.
19Man, KK, Chan, EW, Coghill, D, Douglas, I, Ip, P, Leung, LP, et al. Methylphenidate and the risk of trauma. Pediatrics 2015; 135: 40–8.
20Mikolajczyk, R, Horn, J, Schmedt, N, Langner, I, Lindemann, C, Garbe, E. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA Pediatrics 2015; 169: 391–5.
21Chang, Z, Quinn, PD, Hur, K, Gibbons, RD, Sjolander, A, Larsson, H, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017; 74: 597–603.
22Ruiz-Goikoetxea, M, Cortese, S, Aznarez-Sanado, M, Magallon, S, Alvarez Zallo, N, Luis, EO, et al. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis. Neurosci Biobehav Rev 2018; 84: 63–71.
23Ljung, T, Chen, Q, Lichtenstein, P, Larsson, H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. JAMA Psychiatry 2014; 71: 958–64.
24Liang, SH, Yang, YH, Kuo, TY, Liao, YT, Lin, TC, Lee, Y, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil 2018; 72: 96–105.
25Cortese, S, Adamo, N, Del Giovane, C, Mohr-Jensen, C, Hayes, AJ, Carucci, S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727–38.
26Storebo, OJ, Pedersen, N, Ramstad, E, Kielsholm, ML, Nielsen, SS, Krogh, HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev 2018; 5: CD012069.
27Dalsgaard, S, Kvist, AP, Leckman, JF, Nielsen, HS, Simonsen, M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 2014; 24: 302–10.
28Mazza, M, D'Ascenzo, F, Davico, C, Biondi-Zoccai, G, Frati, G, Romagnoli, E, et al. Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies. Int J Cardiol 2013; 168: 4320–1.
29Chang, Z, Ghirardi, L, Quinn, PD, Asherson, P, D'Onofrio, BM, Larsson, H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 2019; 86: 335–43.
30Olfson, M, Druss, BG, Marcus, SC. Trends in mental health care among children and adolescents. N Engl J Med 2015; 373: 1079.
31Hechtman, L. Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep 2006; 8: 398–408.
32McCarthy, S, Cranswick, N, Potts, L, Taylor, E, Wong, IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009; 32: 1089–96.
33Chen, Q, Sjolander, A, Runeson, B, D'Onofrio, BM, Lichtenstein, P, Larsson, H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348: g3769.
34Kaur, P, Muthuraman, A, Kaur, M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci 2015; 6: 508–21.
35Lee, MJ, Yang, KC, Shyu, YC, Yuan, SS, Yang, CJ, Lee, SY, et al. Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population-based study in Taiwan. J Affect Disord 2016; 189: 110–7.
36Ngwa, JS, Cabral, HJ, Cheng, DM, Pencina, MJ, Gagnon, DR, LaValley, MP, et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol 2016; 16: 148.
38Fine, JP, Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
39R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2019 (https://www.R-project.org/).
40Berger, S. Attention deficit hyperactivity disorder medications in children with heart disease. Curr Opin Pediatr 2016; 28: 607–12.
41Shin, JY, Roughead, EE, Park, BJ, Pratt, NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 2016; 353: i2550.
42Winterstein, AG, Gerhard, T, Kubilis, P, Saidi, A, Linden, S, Crystal, S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345: e4627.
43Man, KKC, Ip, P, Chan, EW, Law, SL, Leung, MTY, Ma, EXY, et al. Effectiveness of pharmacological treatment for attention-deficit/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies. CNS Drugs 2017; 31: 1043–55.
44Chen, VC, Yang, YH, Liao, YT, Kuo, TY, Liang, HY, Huang, KY, et al. The association between methylphenidate treatment and the risk for fracture among young ADHD patients: a nationwide population-based study in Taiwan. PLoS One 2017; 12(3): e0173762.
45Mannuzza, S, Klein, RG, Truong, NL, Moulton, JL 3rd, Roizen, ER, Howell, KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165: 604–9.
46Lee, CT, Chen, VC, Tan, HK, Chou, SY, Wu, KH, Chan, CH, et al. Suicide and other-cause mortality among heroin users in Taiwan: a prospective study. Addict Behav 2013; 38: 2619–23.
47Russell, AE, Ford, T, Russell, G. Barriers and predictors of medication use for childhood ADHD: findings from a UK population-representative cohort. Soc Psychiatry Psychiatr Epidemiol 2019; 54: 1555–64.
48Rucklidge, JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010; 33: 357–73.
49Lichtenstein, P, Larsson, H. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2013; 368: 776.